Research programme: protein therapeutics - Navigo Proteins GmbH

Drug Profile

Research programme: protein therapeutics - Navigo Proteins GmbH

Alternative Names: Human binding proteins research programme - Navigo Proteins; proNGF SPR14; Protein therapeutics research programme - Navigo Proteins; SPR-1401; SPVF 2805-10; SPVF 2805-30; SPVF 2805-40; SPVF-2801; SPVF-2801-10; SPVF-2801-30; SPWF-1501; SPWF-2801; SPWF-2802; SPWF-2803

Latest Information Update: 25 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Scil Proteins
  • Developer Anabasis Pharma; Navigo Proteins
  • Class Nerve growth factors; Recombinant proteins
  • Mechanism of Action Immunomodulators; Neuron stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer; Inflammation

Highest Development Phases

  • No development reported Eye disorders; Inflammation; Solid tumours
  • Discontinued Multiple sclerosis

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Solid-tumours in Germany
  • 16 Jul 2016 No recent reports of development identified for research development in Eye-disorders in Italy
  • 16 Jul 2016 No recent reports of development identified for research development in Inflammation in Germany
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top